The neurometabolic axis: A novel therapeutic target in heart failure

P Chakraborty, SS Po, BJ Scherlag, TW Dasari - Life Sciences, 2023 - Elsevier
Abnormal cardiac metabolism or cardiac metabolic remodeling is reported before the onset
of heart failure with reduced ejection fraction (HFrEF) and is known to trigger and maintain …

Heart failure management with β-blockers: can we do better?

MT de Oliveira Jr, R Baptista… - Current Medical …, 2024 - Taylor & Francis
Heart failure (HF) is associated with disabling symptoms, poor quality of life, and a poor
prognosis with substantial excess mortality in the years following diagnosis. Overactivation …

Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects

A Lymperopoulos, JI Borges, RA Stoicovy - Pharmaceutics, 2024 - mdpi.com
Glucagon-like peptide-1 (GLP-1) is a multifunctional incretin hormone with various
physiological effects beyond its well-characterized effect of stimulating glucose-dependent …

Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor's anti-inflammatory effects

RA Stoicovy, N Cora, A Perez, D Nagliya… - Inflammation …, 2024 - Springer
Background Glucagon-like peptide (GLP)-1 receptor (GLP1R) agonists exert a multitude of
beneficial cardiovascular effects beyond control of blood glucose levels and obesity …

Current Perspective and Mechanistic Insights on Bioactive Plant Secondary Metabolites for the Prevention and Treatment of Cardiovascular Diseases

J Grewal, V Kumar, Y Gandhi, H Rawat… - … Current Drug Targets …, 2023 - ingentaconnect.com
Cardiovascular diseases (CVDs) are one of the most prevalent medical conditions of
modern era and are one of the primary causes of adult mortality in both developing and …